The review found no eligible studies for this question.
Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).